The latest price target for BioCryst Pharma (NASDAQ:BCRX) was reported by RBC Capital on November 5, 2024. The analyst firm set a price target for $10.00 expecting BCRX to rise to within 12 months (a possible 42.25% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for BioCryst Pharma (NASDAQ:BCRX) was provided by RBC Capital, and BioCryst Pharma reiterated their outperform rating.

The last upgrade for BioCryst Pharmaceuticals Inc happened on September 18, 2023 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for BioCryst Pharmaceuticals Inc.

The last downgrade for BioCryst Pharmaceuticals Inc happened on August 8, 2022 when Oppenheimer changed their price target from N/A to N/A for BioCryst Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $10.00 to $10.00. The current price BioCryst Pharma (BCRX) is trading at is $7.03, which is out of the analyst’s predicted range.